{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:00:36Z","timestamp":1776722436245,"version":"3.51.2"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["Grant No. 2023A03J0468"],"award-info":[{"award-number":["Grant No. 2023A03J0468"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Drug-induced pemphigus (DIP) is a distinct subgroup of rare autoimmune blistering disorders, most commonly associated with thiol-containing medications such as penicillamine and captopril. Currently, an increasing number of pemphigus cases induced by non-thiol and non-phenolic drugs have been reported. Herein, we describe a 61-year-old woman with stage IV breast cancer who developed pemphigus foliaceus (PF) after receiving leucogen administration during anti-HER2 (THP) therapy. Cutaneous lesions resolved after leucogen withdrawal and corticosteroid treatment but recurred upon drug re-administration, confirming a probable causal relationship. Histopathological examination and direct immunofluorescence confirmed PF, characterized by intercellular IgG deposition and elevated anti-desmoglein 1 (anti-Dsg1) autoantibody titers. This case highlights that leucogen, a sulfur-containing agent with a thiazolidine-related structure, may represent a potential trigger for DIP, although the underlying mechanism remains speculative.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1745063","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:51:04Z","timestamp":1773211864000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Leucogen-induced pemphigus foliaceus: the first case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Ke","family":"Gui","sequence":"first","affiliation":[{"name":"Department of Dermatology, Guangzhou Dermatology Hospital","place":["Guangzhou, Guangdong, China"]},{"name":"Institute of Dermatology, Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyao","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Guangzhou Dermatology Hospital","place":["Guangzhou, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aili","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Guangzhou Dermatology Hospital","place":["Guangzhou, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwu","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Guangzhou Dermatology Hospital","place":["Guangzhou, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Guangzhou Dermatology Hospital","place":["Guangzhou, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"107299","DOI":"10.1016\/j.intimp.2020.107299","article-title":"Drug-induced pemphigus: A systematic review of 170 patients","volume":"92","author":"Ghaedi","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/0738-081X(93)90158-9","article-title":"Drug-induced pemphigus. II. Pathomechanisms and experimental investigations","volume":"11","author":"Ruocco","year":"1993","journal-title":"Clin Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4103\/aam.aam_162_25","article-title":"Gliptin-induced pemphigus","author":"Jadhav","year":"2025","journal-title":"Ann Afr Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2174\/0118715303361089250320050246","article-title":"The liraglutide-induced pemphigus vulgaris: A first case report highlighting autoimmune risks of GLP-1 receptor agonists","author":"Cai","year":"2025","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"B5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s43556-025-00272-9","article-title":"Autoimmune bullous diseases: pathogenesis and clinical management","volume":"6","author":"Feng","year":"2025","journal-title":"Mol Biomed"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14108","article-title":"Tracing the origins of active amide group-positive drug-induced pemphigus vulgaris along the Silk Road: a case report of candesartan-induced pemphigus vulgaris and review of nonthiol drug-induced pemphigus","volume":"57","author":"Saito","year":"2018","journal-title":"Int J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2014.15.19.8495","article-title":"Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia","volume":"15","author":"Huang","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5144\/0256-4947.2025.9","article-title":"The therapeutic effect of leucogen in treating alcoholic liver cirrhosis with thrombocytopenia or leukopenia","volume":"45","author":"Su","year":"2025","journal-title":"Ann Saudi Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.85144","article-title":"Drug-induced pemphigus foliaceus potentially triggered by piperacillin-tazobactam, linezolid, and additional factors: A report of a rare case","volume":"17","author":"Holi","year":"2025","journal-title":"Cureus"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"New Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0448","article-title":"Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study","volume":"18","author":"Swain","year":"2013","journal-title":"Oncologist"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7150\/jca.86746","article-title":"Adverse event profile differences between trastuzumab emtansine and trastuzumab deruxtecan: A real-world, pharmacovigilance study","volume":"14","author":"Liu","year":"2023","journal-title":"J Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"107055","DOI":"10.1016\/j.imlet.2025.107055","article-title":"Alterations in chemokine receptor-ligand interactions and costimulatory molecules in DC-NK crosstalk: A novel therapeutic approach for pemphigus vulgaris","volume":"276","author":"Hooda","year":"2025","journal-title":"Immunol Lett"},{"key":"B14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2021.08.007","article-title":"Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era","volume":"60","author":"Mand\u00f3","year":"2021","journal-title":"Breast"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2023.08.020","article-title":"Paraneoplastic pemphigus\/paraneoplastic autoimmune multiorgan syndrome: Part I. Clinical overview and pathophysiology","volume":"91","author":"Anderson","year":"2024","journal-title":"J Am Acad Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1745063\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:51:04Z","timestamp":1773211864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1745063\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":15,"alternative-id":["10.3389\/fimmu.2026.1745063"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1745063","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"article-number":"1745063"}}